Header Logo

Connection

Robin Jones to Cardiotoxins

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Cardiotoxins.
Robin Jones
Connection Strength
0.126
Cardiotoxins
  1. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
    View in: PubMed
    Score: 0.126
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.